Krithi Rao Bindal, M.S., Ph.D., M.B.A, president and founderProducing regulatory agency-specific submissions requires extensive expertise. On top of that, the changing regulations make it more challenging for companies. The rejection of drug development and marketing authorization applications can delay the overall drug development process and prevent therapies from reaching patients on time.
Krithi Rao Bindal, M.S., Ph.D., M.B.A, president and founder of Aroga Biosciences, has witnessed firsthand the outcomes of not receiving timely therapies. She lost her maternal grandfather to cancer due to therapy and treatment unavailability.
This ignited her passion for accelerating the development of novel therapeutics through regulatory writing. Utilizing her 15+ years of experience in the regulatory medical writing space, Dr. Bindal set the foundation of Aroga Biosciences, a company driven by the mission to ensure that treatment reaches patients on time. Its comprehensive regulatory writing and submission services—available in a range of therapeutic areas, including gene therapy, biologics, cell therapy, and oncology—ensure high-quality and timely submissions throughout the drug development lifecycle. Aroga regulatory writers understand, interpret, and summarize complex scientific data in a manner that is adherent to regulatory standards and clear to the reader.
“Our motto at Aroga Biosciences is ‘strength from science.’ It drives our passion for delivering high-quality regulatory writing services,” says Dr. Bindal.
The regulatory and medical writing experts at Aroga Biosciences are scientists by training and at heart, giving them the capability and zeal to produce regulatory and medical writing documentation that meets regulatory authorities’ standards.
Ensuring the Highest Quality Regulatory Writing
To ensure submissions meet all standards, the team stays current with continually changing regulations. Many of them, in fact, serve on regulatory affairs committees.
For example, Dr. Bindal serves on Biocom California's Regulatory Affairs Committee, where she works with other regulatory experts to advise on guidance at the national and international levels. Many employees also serve in professional leadership roles, with a few serving on the boards of Regulatory Affairs organizations and Medical Writing associations.
This involvement in the regulatory space allows it to bring knowledge and expertise to a client’s regulatory writing. In addition, its data-driven approach produces documentation that meets the regulator’s standards and focuses the reader on the most important aspect, the science.
Aroga Biosciences pays close attention to quality. The company has a fully devoted team that ensures each draft meets its intense quality metrics. The group takes a sciencedriven approach to check the quality and consistency of messaging while ensuring the documents are submissionready, with proper formatting.
Leveraging the latest AI tools, the team efficiently drives the highest quality deliverables. Aroga Biosciences is also developing AI tools in-house to up its ante in this field.
The team possesses the expertise to create the right content and proper messaging from the preclinical stage to marketing applications. Starting from the non-clinical stage, they summarize preclinical work with scientific reports.
As a team of scientists, Aroga’s regulatory writers have been able to develop submissions at the earliest stages of development, including analyzing data from laboratory notebooks. The Aroga team has a wide range of expertise spanning from non-clinical to clinical writing. The regulatory medical writers are able to participate in study design development with the creation of an initial study protocol all the way up to the analysis of high-level clinical data and messaging when developing submission documents for a marketing application. In addition to regulatory writing, the Aroga team has experience developing manuscripts and conference-related materials for clients. The team excels at creating scientific submissions and ensuring the right messaging for a variety of audiences.
For example, it recently worked on an IND submission with more than 50 non-clinical studies. The non-clinical reports needed to be generated within a stipulated timeframe in parallel with many other submission activities. Through a flexible approach, the team continually pivoted based on the client’s feedback and helped them manage the IND submission project quickly, focusing on every detail. Impressed by the accountability and quality of services, the client signed an agreement for future submissions.
Process-Driven Approach to Ensure Success
A process-driven firm, Aroga Biosciences has a system to understand resourcing needs, regulatory strategy, and submission planning strategy. This approach begins at the leadership level at the start of every project to appropriately implement procedures for project management. It uses different project management and writing tools from the beginning until the end of any submission and ensures proper collaboration and communication with clients. In case of a strategy change, Aroga Biosciences quickly pivots its approach to resolve it. Aroga Biosciences has developed specialized internal processes and templates to streamline project workflows in order to create a seamless experience for project teams.
Dr. Bindal engages with clients through check-in meetings twice a month to ensure everything is progressing on track. At the end of the project, Aroga Biosciences seeks direct client feedback to ensure the project’s success. Aroga Biosciences’ regulatory writers have the skilled ability to manage several key stakeholders and ensure the utmost professionalism. Aroga prides itself on its ability to create long-lasting professional relationships, which has resulted in repeat work and long-term clients.
Functioning as an extension of a client’s in-house team, the Aroga Biosciences team never hesitates to go the extra mile to support them. They believe everything is interdependent, and the team follows through with the other aspects of the project to ensure all of the dependencies of a project are in place and fully communicated. The follow-through is essential for Aroga Biosciences to work more efficiently and to better support clients in meeting their goals.
Our motto at Aroga Biosciences is ‘strength from science.’ It drives our passion for delivering high-quality regulatory writing services
Many other clients also appreciate the Aroga team for supporting them on crucial regulatory submissions.
“Thank you, Aroga team, for the quality of service you provided to support our IND. You have skilled writers who are equally as invested in the project. We sincerely appreciate the flexibility, level of detail, and accountability you demonstrated on this project and the way you conduct business as a whole. We look forward to working with your team again on our next IND,” says the head of regulatory affairs of a renowned biotech company.”
“We had the pleasure of teaming up with Krithi and her team at Aroga while working on an important regulatory submission."
"They demonstrated deep knowledge, professionalism, flexibility, and dedication. Things went as planned, and the objectives were accomplished under aggressive timelines. THANK YOU, Aroga! We look forward to working with you again,” says the chief operating officer of another biotech organization.”
Aroga Biosciences continues to support the progress of many revolutionary therapeutics with its ability to quickly understand data sets and clinical trial design and effectively communicate it to regulators. To enhance its capabilities, the company has added redaction services and layperson summaries to the service portfolio. New regulations increase the need to publish clinical and product data to the general public. Its services help clients protect the confidentiality of patients along with serving the patient community.
Fostering a Positive Culture
A friendly and positive culture is fostered within the organization, where the team members always support each other.
"Aroga is a company that values its employees and provides the opportunity for both professional and personal development. I have been at Aroga for almost two years and strengthen my document development, communication, and project management skills. Every day presents a new learning opportunity. We work on many different document types including clinical study reports, protocols, investigator brochures, and manuscripts. Aroga strives for a friendly and team-oriented work environment. My colleagues at Aroga are highly talented and encouraging. We are a team of medical writers who focus on making a positive impact to our clients and are passionate about medical writing. I am proud to be a part of the Aroga family," says regulatory medical writer, Aroga Biosciences”
The Principal Regulatory Medical Writer at Aroga appreciates the culture Dr. Bindal has created within the company and says,
“The work environment is highly collaborative, and everyone is highly motivated. Krithi organizes regulatory hot topics discussions and social activities that keep us informed on what is happening in the regulatory field and encourage productive and thoughtful discussions. The various social activities during the year promote a sense of belonging and team building, a foundation for the good team environment that Aroga has built. Working with Aroga Bio has been a fantastic experience for me. It is inspiring to work with a great team of trained scientists who are also excellent medical writers.”
They believe in solving problems collaboratively to serve the industry and patients effectively. Aroga Biosciences is also actively engaged with nonprofit organizations, particularly in the oncology space. It recently collaborated with an NGO to sponsor the annual CureSearch walk—which is raising funds for children with cancer—to stay true to Aroga’s goal of serving patients in need.
“While we indirectly service the patient community with our regulatory writing, we directly support them through nonprofit organizations,”
says Dr. Bindal. Aroga Biosciences’ services are not limited to the U.S. It serves clients in APAC and European regions. It also explores the latest technologies within clinical research and regulatory development to make the process more efficient and deliver high-quality documents.
For its contribution to the therapeutic world, Aroga Biosciences received many awards last year. For example, Dr. Bindal was recognized as a top leader of influence in life science by the San Diego Business Journal. Aroga Biosciences was also selected as a top emerging CRO in 2022 by PharmaTech Outlook.
Aroga Biosciences is driven by its passion and commitment to be part of the treatment development process from the beginning of a program to eventual approval and is guided by the strength from science.
Choosing a Gold Standard Scientific Communications Partner
Life sciences companies are dealing with a much heavier documentation burden than they were even a few years ago. Development programs now generate large volumes of clinical, regulatory, safety and scientific material that must remain consistent across internal teams, regulatory agencies and external stakeholders, often while timelines and development strategies are still evolving. For executives selecting scientific communications and regulatory writing partners, the challenge is no longer simply finding a vendor that can produce documents. The real need is for a partner that can help maintain clarity, consistency and submission readiness across the entire development process.
One of the biggest risks in this environment is fragmentation. Many sponsors rely on separate providers for medical writing, quality control, publishing and regulatory submissions. While that structure can work in slower-moving programs, it often creates problems once timelines tighten or development priorities shift. Every additional handoff increases the chance of inconsistent messaging, duplicated reviews, formatting delays or disconnects between source data and final submission documents. Those issues may seem small individually, but they can quickly create larger operational and regulatory problems under compressed deadlines.
The stronger service models tend to integrate writing, review, publishing and submission preparation more closely. Scientific communication in life sciences is not just about assembling technically correct documents. It requires people who can interpret clinical findings, safety data, CMC information and nonclinical evidence in a way that makes the scientific rationale easier for reviewers to follow. A document can contain all the required information and still fail to communicate the bigger picture clearly. That is why scientific judgment matters just as much as writing ability.
This becomes even more important in complex therapeutic areas such as oncology, rare disease, neurology, cell therapy and gene therapy, where development programs often involve evolving datasets, specialized endpoints and close coordination across scientific and regulatory teams. In these settings, companies benefit from partners that can stay close to the broader development narrative rather than treating every deliverable as an isolated assignment.
Speed also needs to be managed carefully. Life sciences companies frequently operate under aggressive timelines, but rushing documents through development often creates more downstream work later. Strong partners balance flexibility with discipline by adapting to sponsor workflows and communication styles while still maintaining rigorous standards around accuracy, version control, quality review and regulatory alignment. Fast turnaround only becomes valuable when the underlying quality remains consistent.
Technology can support that process, but it is rarely the deciding factor on its own. Project tracking systems, validation tools and publishing software can improve oversight and reduce avoidable errors, but they still depend on experienced scientific and regulatory teams behind them. Companies evaluating providers should look closely at how quality is maintained across the full document lifecycle and how potential issues are identified before they begin affecting timelines or submission readiness.
Aroga Biosciences provides scientific communications, regulatory writing and submission support across clinical, safety, CMC, nonclinical and publication-focused workstreams. Its services also include quality control, regulatory operations, publishing support and submission formatting, giving sponsors a more integrated path from document development through regulatory delivery. The company’s model appears particularly well suited for biotech and pharmaceutical organizations managing complex IND and FDA-related milestones where consistency, scientific understanding and close coordination across deliverables become critical.
...Read more
